GoodRx, a platform utilized by nearly 25 million consumers and over one million healthcare professionals annually for prescription savings in the U.
S., announced its role as an integrated pricing source for pharmaceutical companies on TrumpRx. TrumpRx is a website that lists discounted cash prices from pharmaceutical manufacturers, facilitating consumer access to selected discounts through underlying partner platforms. Since 2011, GoodRx has facilitated over $100 billion in savings on medication costs for Americans.
At launch, GoodRx provides the integrated pricing source for Pfizer, covering over 30 of Pfizer’s essential brand medications. Additional manufacturer integrations are anticipated to follow. Wendy Barnes, President and CEO of GoodRx, stated, “Transparent direct-to-consumer prescription pricing helps to ensure millions of Americans have access to the healthcare they deserve.”
Barnes added, “GoodRx gives manufacturers a proven way to launch discounted cash pricing at scale and extend it directly into TrumpRx. We’re starting with essential brand medications from Pfizer and other manufacturers, with additional programs coming soon. Together, we’re turning the promise of prescription drug affordability into a reality for millions of Americans.”
Coinciding with the TrumpRx launch, Pfizer is offering significant discounts for more than 30 of its essential brand medications, including those for women’s health, migraine, arthritis, and rare diseases. Eligible patients can find these prices on TrumpRx and access GoodRx-enabled savings, which can range as high as 85% and average 50% for the majority of Pfizer’s primary care treatments and select specialty brands. GoodRx has also launched a Pfizer-branded digital storefront to assist consumers in finding these prices.
This integration positions GoodRx as an operational layer for emerging pharmaceutical pricing models. GoodRx offers manufacturers a scalable solution to publish discounted cash prices and extend them to TrumpRx by unifying pricing, pharmacy enablement, and consumer experience. This approach aims to reduce complexity, enabling manufacturers to implement policy-aligned pricing programs, such as most favored nation (MFN), at a national scale, thereby reaching more patients and supporting consistent savings at the pharmacy.
